(Q34574384)

3 August 2017

1 reference

title

An evidence-based evaluation of the gastrointestinal safety of coxibs (English)

1 reference

3 August 2017

Claire Bombardier

1

1 reference

3 August 2017

language of work or name

English

0 references

publication date

1 March 2002

1 reference

American Journal of Cardiology

3 August 2017

published in

1 reference

3 August 2017

volume

89

1 reference

3 August 2017

issue

6A

1 reference

3 August 2017

page(s)

3D-9D

1 reference

Arachidonic acid oxygenation by COX-1 and COX-2. Mechanisms of catalysis and inhibition

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902231-2

Genetic and pharmacological analysis of prostanoid receptor function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902231-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902231-2

7 January 2021

Cyclooxygenases 1 and 2

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902231-2

Characterization of the promoter of human prostaglandin H synthase-1 gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902231-2

Cyclooxygenase-2 and its regulation in inflammation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902231-2

Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902231-2

Detection of COX-1 and COX-2 isoforms in synovial fluid cells from inflammatory joint diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902231-2

Cyclooxygenase-1 and -2 expression in rheumatoid synovial tissues. Effects of interleukin-1 beta, phorbol ester, and corticosteroids.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902231-2

Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902231-2

Characterization of Prostaglandin G/H Synthase 1 and 2 in rat, dog, monkey, and human gastrointestinal tracts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902231-2

Physiological regulation of cyclooxygenase-2 in the kidney

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902231-2

Transforming growth factor-beta1 enhances Ha-ras-induced expression of cyclooxygenase-2 in intestinal epithelial cells via stabilization of mRNA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902231-2

The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902231-2

Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902231-2

The coxibs, selective inhibitors of cyclooxygenase-2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902231-2

Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902231-2

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902231-2

Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902231-2

Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip. Rofecoxib Phase III Protoco

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902231-2

Celecoxib: a review of its use in osteoarthritis, rheumatoid arthritis and acute pain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902231-2

A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis. Rofecoxib/Ibuprofen Comparator Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902231-2

Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial. The Rofecoxib Osteoarthritis Endoscopy M

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902231-2

Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902231-2

Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902231-2

Comparison of rofecoxib and celecoxib, two cyclooxygenase-2 inhibitors, in postoperative dental pain: a randomized, placebo- and active-comparator-controlled clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902231-2

Analgesic efficacy of the cyclooxygenase-2-specific inhibitor rofecoxib in post-dental surgery pain: a randomized, controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902231-2

Rofecoxib, a specific cyclooxygenase-2 inhibitor, in primary dysmenorrhea: a randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902231-2

A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902231-2

Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902231-2

Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902231-2

10.1016/S0002-9149(02)02231-2

7 January 2021

Identifiers

DOI

1 reference

3 August 2017

1 reference